中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2015年
1期
12-15
,共4页
肾肿瘤%人类主要组织相容性复合物Ⅰ类相关链A%自然杀伤细胞
腎腫瘤%人類主要組織相容性複閤物Ⅰ類相關鏈A%自然殺傷細胞
신종류%인류주요조직상용성복합물Ⅰ류상관련A%자연살상세포
Renal tumor%Major histocompatibility complex class-Ⅰ related chain A%Natural killer cell
目的 探讨肾肿瘤患者人类主要组织相容性复合物Ⅰ类相关链A(major histocompatibility complex class-Ⅰ related chain A,MICA)的表达及临床意义. 方法 选取2013年3-7月收治的60例肾肿瘤患者作为研究组,男37例,女23例.年龄34 ～ 76岁,平均46岁.肾透明细胞癌48例,肾血管平滑肌脂肪瘤12例.病理分期:T1期20例,T2期14例,T3期10例,T4期4例.淋巴结转移11例,其他器官转移4例.20例健康体检者为对照组,男10例,女10例.年龄24～50岁,平均31岁.利用ELISA法测定两组血清中分泌型MICA(soluble MICA,sMICA)分子的水平.分析sMICA分子含量与肾肿瘤的性质、肾癌分期、淋巴结及器官转移的关系.免疫组化染色法测定15例肾癌及癌旁组织标本的MICA分子表达情况.实时定量PCR法测定9例肾癌和3例癌旁组织标本的MICA-mRNA表达情况. 结果 48例肾癌、12例肾血管平滑肌脂肪瘤、20例对照组的血清sMICA水平分别为(348.5±32.5)、(289.3±30.4)、(168.4±43.2) pg/ml,研究组与对照组比较差异有统计学意义(P＜0.05),肾癌组与肾血管平滑肌脂肪瘤组比较差异有统计学意义(P＜0.05).肾肿瘤T1、T2、T3、T4期的sMICA水平分别为(304.3±27.4)、(308.4±26.8)、(368.3±33.4)、(378.4±43.4) pg/ml,T1、T2期间比较差异无统计学意义(P＞0.05),其余各分期间比较差异有统计学意义(P＜0.05).伴有淋巴结转移组与无淋巴结转移组的sMICA水平分别为(326.2±32.4)、(319.4±32.5) pg/ml,差异无统计学意义(P＞0.05).伴有其他器官转移组与无其他器官转移组的sMICA水平分别为(373.4±45.4)、(346.4±31.5) pg/ml,差异有统计学意义(P＜0.05).免疫组化染色法证实MICA分子在癌组织的细胞表面高表达,而在癌旁细胞表面不表达.实时定量PCR法检测MICA-mRNA在癌组织的表达量(2.03)明显高于癌旁组织(0.77),差异有统计学意义(P＜0.05). 结论 MICA在肾肿瘤中高度表达,其表达高低与肾肿瘤的性质、肾癌分期及转移有关.
目的 探討腎腫瘤患者人類主要組織相容性複閤物Ⅰ類相關鏈A(major histocompatibility complex class-Ⅰ related chain A,MICA)的錶達及臨床意義. 方法 選取2013年3-7月收治的60例腎腫瘤患者作為研究組,男37例,女23例.年齡34 ～ 76歲,平均46歲.腎透明細胞癌48例,腎血管平滑肌脂肪瘤12例.病理分期:T1期20例,T2期14例,T3期10例,T4期4例.淋巴結轉移11例,其他器官轉移4例.20例健康體檢者為對照組,男10例,女10例.年齡24～50歲,平均31歲.利用ELISA法測定兩組血清中分泌型MICA(soluble MICA,sMICA)分子的水平.分析sMICA分子含量與腎腫瘤的性質、腎癌分期、淋巴結及器官轉移的關繫.免疫組化染色法測定15例腎癌及癌徬組織標本的MICA分子錶達情況.實時定量PCR法測定9例腎癌和3例癌徬組織標本的MICA-mRNA錶達情況. 結果 48例腎癌、12例腎血管平滑肌脂肪瘤、20例對照組的血清sMICA水平分彆為(348.5±32.5)、(289.3±30.4)、(168.4±43.2) pg/ml,研究組與對照組比較差異有統計學意義(P＜0.05),腎癌組與腎血管平滑肌脂肪瘤組比較差異有統計學意義(P＜0.05).腎腫瘤T1、T2、T3、T4期的sMICA水平分彆為(304.3±27.4)、(308.4±26.8)、(368.3±33.4)、(378.4±43.4) pg/ml,T1、T2期間比較差異無統計學意義(P＞0.05),其餘各分期間比較差異有統計學意義(P＜0.05).伴有淋巴結轉移組與無淋巴結轉移組的sMICA水平分彆為(326.2±32.4)、(319.4±32.5) pg/ml,差異無統計學意義(P＞0.05).伴有其他器官轉移組與無其他器官轉移組的sMICA水平分彆為(373.4±45.4)、(346.4±31.5) pg/ml,差異有統計學意義(P＜0.05).免疫組化染色法證實MICA分子在癌組織的細胞錶麵高錶達,而在癌徬細胞錶麵不錶達.實時定量PCR法檢測MICA-mRNA在癌組織的錶達量(2.03)明顯高于癌徬組織(0.77),差異有統計學意義(P＜0.05). 結論 MICA在腎腫瘤中高度錶達,其錶達高低與腎腫瘤的性質、腎癌分期及轉移有關.
목적 탐토신종류환자인류주요조직상용성복합물Ⅰ류상관련A(major histocompatibility complex class-Ⅰ related chain A,MICA)적표체급림상의의. 방법 선취2013년3-7월수치적60례신종류환자작위연구조,남37례,녀23례.년령34 ～ 76세,평균46세.신투명세포암48례,신혈관평활기지방류12례.병리분기:T1기20례,T2기14례,T3기10례,T4기4례.림파결전이11례,기타기관전이4례.20례건강체검자위대조조,남10례,녀10례.년령24～50세,평균31세.이용ELISA법측정량조혈청중분비형MICA(soluble MICA,sMICA)분자적수평.분석sMICA분자함량여신종류적성질、신암분기、림파결급기관전이적관계.면역조화염색법측정15례신암급암방조직표본적MICA분자표체정황.실시정량PCR법측정9례신암화3례암방조직표본적MICA-mRNA표체정황. 결과 48례신암、12례신혈관평활기지방류、20례대조조적혈청sMICA수평분별위(348.5±32.5)、(289.3±30.4)、(168.4±43.2) pg/ml,연구조여대조조비교차이유통계학의의(P＜0.05),신암조여신혈관평활기지방류조비교차이유통계학의의(P＜0.05).신종류T1、T2、T3、T4기적sMICA수평분별위(304.3±27.4)、(308.4±26.8)、(368.3±33.4)、(378.4±43.4) pg/ml,T1、T2기간비교차이무통계학의의(P＞0.05),기여각분기간비교차이유통계학의의(P＜0.05).반유림파결전이조여무림파결전이조적sMICA수평분별위(326.2±32.4)、(319.4±32.5) pg/ml,차이무통계학의의(P＞0.05).반유기타기관전이조여무기타기관전이조적sMICA수평분별위(373.4±45.4)、(346.4±31.5) pg/ml,차이유통계학의의(P＜0.05).면역조화염색법증실MICA분자재암조직적세포표면고표체,이재암방세포표면불표체.실시정량PCR법검측MICA-mRNA재암조직적표체량(2.03)명현고우암방조직(0.77),차이유통계학의의(P＜0.05). 결론 MICA재신종류중고도표체,기표체고저여신종류적성질、신암분기급전이유관.
Objective To explore the expression and clinical value of major histocompatibility complex class-Ⅰ related chain A (sMICA) molecule in serum of patients with renal tumor.Methods From March 2013 to July 2013,60 patients with renal tumor,including 37 male patients and 23 female patients were enrolled in this study as experimental group.The mean age was 46 years (range 34-76 years).The pathological diagnosis included renal cell carcinoma in 48 cases and renal angiomyolipoma in 12 cases.The stage classification included T1 stage in 20 cases,T2 stage in 14 cases,T3 stage in 10 cases and T4 stage in 4 cases.Lymphatic metastases were found in 11 cases and metastases in other organs were found in 4 cases.Another 20 healthy volunteers were enrolled as control group,including 10 male and 10 female.The mean age was 31 years (range 24-50 years).The ELISA method was used to detect the soluble MICA's (sMICA) level in serum.And the results were compared with tumor's malice,TNM pathology stages,metastasis.In 15cases with renal cell carcinoma,the expression of MICA molecule in tumor masses and paraneoplastic masses was measured by immunohistochemical (IHC) method.The quantitative expression of MICA-mRNA was detected by RT-PCR in 9 tumor masses and 3 paraneoplastic masses.Results The level of sMICA in renal malignant tumor group was (348.5±32.5) pg/ml,while the sMICA's level in benign renal tumor groups was (289.3±30.4) pg/ml and that in the control group was (168.4±43.2) pg/ml.The level of sMICA in malignant group is statistically higher than that in benign group and control group (P＜0.05).The level of sMICA in T1 、T2 、T3 and T4 stage was (304.3±27.4),(308.4±26.8),(368.3±33.4),(378.4±43.4) pg/ml,respectively.Insignificant difference only demonstrated between T1 and T2 stage.The level of sMICA in those patients with and without lymphatic metastasis was (326.2±32.4),(319.4±32.5) pg/ml,respectively (P＞0.05).Significant difference in the sMICA level could also be observed between patients with other organ metastasis (373.4±45.4) pg/ml and those without metastasis (346.4±31.5) pg/ml (P＜0.05).The IHC results revealed that high expression of MICA molecule in tumor cell.However,this oppsite result was demonstrated in cells located in paraneoplastic tissues.In the results of RT-PCR,the MICA-mRNA level (2.03) in tumor masses was significantly higher than that in pareneoplastic masses (0.77) (P＜0.05).Conclusions MICA highly expressed in renal tumor,and its expression correlates with tumor's malice,TNM pathologic stages,and metastasis.
